174 - Vaccine Challenging Cases

Friday, October 13, 2023

1:45 PM – 3:00 PM US ET

Location: 205 ABC

All relevant financial disclosures have been mitigated.

Interactive Moderator(s)

Catherine Mary Healy, MD, FIDSA (she/her/hers)

Associate Professor of Pediatrics
Baylor College of Medicine
Houston, TX, United States
Lisa Jackson, MD, MPH (she/her/hers)

Senior Investigator
Kaiser Permanente Washington Health Research Institute
Seattle, WA, United States

Slides

Panelist(s)

KT

Kawsar Talaat, MD (she/her/hers)

Associate Professor
Johns Hopkins Bloomberg School of Public Health
Baltimore, MD, United States
Pia Pannaraj, MD, MPH (she/her/hers)

Professor
Department of Pediatrics / Department of Molecular Microbiology and Immunology
University of California San Diego
La Jolla, CA, United States
SO

Sean O'Leary, MD, MPH (he/him/his)

Professor of Pediatrics
University of Colorado Anschutz Medical Campus
Aurora, CO, United States

Disclosure(s):

Catherine Mary Healy, MD, FIDSA: Dexcom Inc: Stocks/Bonds (Ongoing); Emmes Corporation: SMC member (Terminated); Intuitive Surgical Inc: Stocks/Bonds (Ongoing); Quidel Corporation: Stocks/Bonds (Ongoing); Vapotherm: Stocks/Bonds (Ongoing)

Lisa Jackson, MD, MPH: Pfizer, Inc.: Grant/Research Support (Ongoing)

Kawsar R. Talaat, MD: Intralytix: Advisor/Consultant (Ongoing); Merck: Advisor/Consultant (Ongoing); NIAID: DSMB (Ongoing); Pfizer: Grant/Research Support (Ongoing), Pfizer contract with institution (Ongoing); Sanofi: Grant/Research Support (Ongoing); Takeda: Advisor/Consultant (Ongoing)

Pia S. Pannaraj, MD, MPH: AstraZeneca: Grant/Research Support (Terminated, June 14, 2023); Pfizer: Grant/Research Support (Terminated, June 14, 2023)

Sean O'Leary: No financial relationships to disclose

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-23-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe ACIP guidelines for specific vaccinations;
explain controversies in applying guidelines to specific challenging vaccine questions;
investigate how guidelines are modified in specific targeted situations;
describe how specific vaccine guidelines apply to special host populations.